Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses

被引：0
作者：
Kenji Watanabe
Satoshi Motoya
Haruhiko Ogata
Takanori Kanai
Toshiyuki Matsui
Yasuo Suzuki
Mitsuhiro Shikamura
Kenkichi Sugiura
Kazunori Oda
Tetsuharu Hori
Takahiro Araki
Mamoru Watanabe
Toshifumi Hibi
机构：
[1] Hyogo College of Medicine,Department of Intestinal Inflammation Research
[2] Hokkaido Prefectural Welfare Federation of Agricultural Cooperative,IBD Center
[3] Sapporo-Kosei General Hospital,Endoscopic Center
[4] Keio University School of Medicine,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[5] Keio University School of Medicine,Department of Gastroenterology
[6] Fukuoka University Chikushi Hospital,Department of Internal Medicine
[7] Toho University Medical Center Sakura Hospital,Takeda Development Center Japan
[8] Takeda Pharmaceutical Company Limited,Regenerative Medicine Unit
[9] Takeda Pharmaceutical Company Limited,Department of Gastroenterology and Hepatology
[10] Tokyo Medical and Dental University,Center for Advanced Inflammatory Bowel Disease Research and Treatment
[11] Kitasato University Kitasato Institute Hospital,undefined
来源：
Journal of Gastroenterology | 2020年 / 55卷
关键词：
Crohn’s disease; Vedolizumab; α; β; integrin; Biologic; Randomized controlled trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：291 / 306
页数：15
相关论文
共 94 条
  • [1] Ng WK(2016)Changing epidemiological trends of inflammatory bowel disease in Asia Intest Res. 14 111-119
  • [2] Wong SH(2018)ACG clinical guideline: management of Crohn’s disease in adults Am J Gastroenterol. 113 481-517
  • [3] Ng SC(2008)Nutritional therapy for active Crohn’s disease World J Gastroenterol 14 4420-3-99
  • [4] Lichtenstein GR(2016)Loss of response to anti-TNFs: definition, epidemiology, and management Clin Transl Gastroenterol. 5 79-1444
  • [5] Loftus EV(2013)Clinical use of anti-TNF therapy and increased risk of infections Drug Healthc Patient Saf. 10 1437-721
  • [6] Isaacs KL(2016)An overview of the mechanism of action of the monoclonal antibody vedolizumab J Crohns Colitis. 369 711-627
  • [7] Smith PA(2013)Vedolizumab as Induction and maintenance therapy for Crohn’s disease N Engl J Med. 147 618-986
  • [8] Roda G(2014)Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 47 979-11537
  • [9] Jharap B(2015)Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Nat Genet. 20 11525-196
  • [10] Neeraj N(2014)Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives World J Gastroenterol. 12 193-138
12345678910